Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug that may help decrease the chances of relapse after
Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug
involved in this study is:
• Ruxolitinib
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Ohio State University Vanderbilt University Washington University School of Medicine